Multi-center, open-label, single arm study to Evaluate the preference regarding convenience of medication, efficacy and safety of Sugamet XR tab. 5/1000mg in patients with Type 2 diabetes and renal diseases

Inclusion Criteria:

• Aged ≥60 years
• Subjects with type 2 diabetes mellitus
• Subjects treated with DPP-4 inhibitor and 1,000mg/day dose of metformin 1T/qd for at least 8 weeks prior to screening
• Subjects with HbA1c≤7.5% at screening
• Subjects with 45mL/min/1.73m2≤eGFR≤90mL/min/1.73m2 at screening
• Subjects with fasting glucose≤200 at screening
• Subjects with 18.5kg/m2≤BMI≤40kg/m2 at screening

Exclusion Criteria:

• Patients with type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus
• ESRD or Patients who have kidney dialysis
• Subjects with ALT and AST 3 times or higher than upper normal range